BIOMEDICAL CELL PRODUCT BASED ON MAMMALIAN MESENCHYMAL STROMAL CELLS AND HEXAPEPTIDE Russian patent published in 2022 - IPC A61K9/08 A61K9/72 A61K35/28 A61K38/08 A61P11/00 

FIELD: cell biology and medicine.

SUBSTANCE: present invention relates to cell biology and medicine, in particular to a biomedical cell product for the treatment of lung disease associated with elevated levels of interleukin-6, in the form of an aqueous suspension. The product includes mammalian mesenchymal stromal cells in an amount of 0.1×10⁶ to 10.0×10⁶ cells/ml and a hexapeptide of the formula H-Tyr-D-Ala-Gly-Phe-Leu-Arg-OH or a pharmaceutically acceptable salt thereof in an amount of from 0.1 to 10.0 mg/ml. The preferred pharmaceutically acceptable salt of the invention is the diacetate. Said product is used in the treatment of lung disease associated with elevated levels of interleukin-6 selected from the group consisting of acute inflammatory lung disease, acute respiratory distress syndrome, pneumonia, chronic obstructive pulmonary disease, emphysema, asthma, COVID-19.

EFFECT: present invention makes it possible to increase the viability of MSCs in the composition of BMCP through the use of the H-Tyr-D-Ala-Gly-Phe-Leu-Arg-OH hexapeptide and, thus, to improve the therapeutic characteristics of these products.

4 cl, 12 tbl, 6 ex